CellSource Co

CellSource Co FCF/Debt

The Free Cash Flow to Debt Ratio of CellSource Co (4880.T) as of Oct 27, 2026 is 511.13 %. In the previous year, Free Cash Flow to Debt Ratio was 127.40 % — a change of 301.20% (higher).

FCF/Debt

511.13 %

YoY

301.20%

Last updated:

Free Cash Flow to Debt Ratio of CellSource Co is 2025 511.13 % . Free Cash Flow to Debt Ratio of CellSource Co was 2024 127.40 % . It decreases by 301.20% higher compared to the previous year.

The CellSource Co FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2019
1,982.69 JPY
Jan 1, 2020
7,004.74 JPY
Jan 1, 2021
76,878.40 JPY
Jan 1, 2023
511.18 JPY
Jan 1, 2024
127.40 JPY
Jan 1, 2025
511.13 JPY
The CellSource Co FCF/Debt history
YEARFCF/DebtYoY
511.13 %+301.20%
127.40 %-75.08%
511.18 %-99.34%
76,878.40 %+997.52%
7,004.74 %+253.30%
1,982.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Free Cash Flow to Debt Ratio of CellSource Co is 511.13 % in 2025.

Free Cash Flow to Debt Ratio of CellSource Co changed from 127.40 % to 511.13 %, representing a 301.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio CellSource Co since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's CellSource Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — CellSource Co

All Key Metrics — CellSource Co